What Verdica's 799 score means for ALEMBIC PHARMS LTD
Alembic Pharms Ltd scores 799 out of 850 on Verdica's composite compliance index, placing it in the strong band (740–799). This score reflects consistent regulatory adherence across the three dimensions Verdica monitors: product approval pathways, manufacturer profile integrity, and active FDA and DEA compliance.
A score of 799 indicates that Alembic operates within established regulatory frameworks with minimal compliance friction. It is not a perfect score—the 51-point gap from the maximum 850 suggests some documented deviations or areas where regulatory bodies have flagged concerns—but it reflects a provider that has demonstrated the operational maturity and quality controls expected of a legitimate, licensed pharmaceutical manufacturer. For a business owner or procurement team, this score suggests low regulatory risk compared to industry peers, though it does not eliminate the need for standard due diligence before engagement.
No independent customer reviews are currently indexed for this entity, so Verdica's assessment is based entirely on objective regulatory and licensing data rather than subjective experience reports.
How the sub-scores break down
Product Approval (850 / 850): A perfect score here means all products Alembic manufactures have completed required approval pathways—whether through FDA New Drug Application (NDA), Abbreviated NDA (ANDA), or other regulatory mechanisms. This dimension reflects whether products are legally authorized for sale and manufacturing is documented. A perfect mark indicates zero documented lapses in product authorization status.
Manufacturer Profile (720 / 850): This score reflects the condition and legitimacy of Alembic's operational credentials as recorded in state pharmacy boards and federal registries. It tracks licensing status, facility registration, corporate standing, and any historical compliance notes. A score of 720 is respectable but notably lower than product approval, suggesting there may be minor documentation gaps, historical citations, or administrative findings that regulators have recorded. This does not mean the company is unlicensed or rogue; it indicates room for improvement in operational or procedural compliance.
FDA Compliance (830 / 850): This dimension tracks adherence to Current Good Manufacturing Practice (CGMP), adverse event reporting, facility inspections, and product recall records maintained by the FDA. A score of 830 is strong and suggests Alembic has passed FDA scrutiny and maintains production standards. The 20-point gap from perfect may reflect minor inspection observations, documentation corrections, or other non-critical findings that the FDA has recorded but that did not result in warning letters or enforcement action.
What regulators track for pharmacy providers
State boards of pharmacy maintain licensing records, disciplinary histories, and facility registrations for all manufacturers. They track whether licenses are current, renewed on schedule, and whether the entity has faced sanctions, suspensions, or revocations.
The FDA monitors manufacturing facilities through inspections (typically unannounced) and maintains records of compliance observations, warning letters, import alerts, and product recalls. They assess whether manufacturers follow CGMP standards, properly label products, and report adverse events to MedWatch.
The DEA tracks controlled substance manufacturing and distribution through licensure and quota systems. Pharmacies and manufacturers must maintain separate DEA registrations and comply with recordkeeping, security, and diversion-prevention protocols.
Violations that lower scores include unlicensed operation, unresolved warning letters, repeated inspection failures, product recalls due to manufacturing defects, unresolved adverse event reports, and failure to renew licenses or registrations on time.
Bottom line
Alembic Pharms Ltd presents a low-to-moderate regulatory risk profile suitable for most procurement and partnership contexts. Before engagement, verify current licensing status directly with relevant state and federal agencies, confirm product-specific approvals for your intended use, and request a recent FDA inspection summary if available.